Limited effectiveness of FK506 administration for ongoing rejection in heterotopic rat heart transplantation.
A comparison was made of the histological findings for myocardial tissue of heterotopic transplanted rat hearts administered with FK506. ACI rats were used as donors and Lewis rats as recipients. FK506 was used for 6 days except for group I (control group). Group II received 0.32 mg/kg/day of FK506 from the day of operation while group III was given the same dosage from the 4th day after transplantation. Group IV was given 1.28 mg/kg/day of the agent from the day of grafting and group V received the same dose from the 4th postoperative day. The graft survival time was longer for all groups given FK506, but was significantly longer only for groups administered with FK506 from the day of operation. Histological studies performed 10 and 20 days after transplantation showed that a moderate rejection was seen in about half of the grafts receiving FK506 from the 4th day after grafting. An ultrastructural study of these cases showed that infiltrating large lymphocytes still remained in the interstitial tissues and that the cytoplasmic organelles of the myocytes had been focally destroyed. These results suggest that, although FK506 suppressed any further rejection, the effect might be limited and the myocardial changes of the cardiac graft might persist even after administration for ongoing rejection.
Hisatomi
K
K
Second Department of Surgery, Kurume University School of Medicine, Japan.
Sato
T
T
Nishimi
M
M
Hirano
A
A
Isomura
T
T
Aoyagi
S
S
Kosuga
K
K
Ohishi
K
K
D000818:Animals; D006084:Graft Rejection / Q000188:drug therapy* / Q000276:immunology / Q000517:prevention & control; D006085:Graft Survival / Q000187:drug effects; D016027:Heart Transplantation / Q000276:immunology* / Q000473:pathology; D008214:Lymphocytes; D008297:Male; D009206:Myocardium / Q000276:immunology* / Q000473:pathology / Q000648:ultrastructure; D051381:Rats; D011912:Rats, Inbred ACI; D011917:Rats, Inbred Lew; D011919:Rats, Inbred Strains; D016559:Tacrolimus / Q000494:pharmacology / Q000627:therapeutic use*; D016042:Transplantation, Heterotopic / Q000276:immunology* / Q000473:pathology
D016559:Tacrolimus